Skip to main content
. 2018 Sep 27;13(9):e0204745. doi: 10.1371/journal.pone.0204745

Fig 4. Recurrence-free survival (RFS) rates after TURBT for NMIBC in patients with low (< 17.98%) and high (≥ 17.98%) percentages of Foxp3+ cells among CD3+ cells by sub-groups according to risk stratification and adjuvant intravesical treatment.

Fig 4

(A) RFS rates after TURBT for low-risk NMIBC patients without adjuvant intravesical treatment. Black line: patients with low Foxp3+ cells (n = 21). Red line: patients with high Foxp3+ cells (n = 10). P = 0.220, log-rank test. (B) RFS rates after TURBT for intermediate-risk NMIBC patients without adjuvant intravesical treatment. Black line: patients with low Foxp3+ cells (n = 11). Red line: patients with high Foxp3+ cells (n = 12). P = 0.114, log-rank test. (C) RFS rates after TURBT for intermediate-risk NMIBC patients with intravesical THP treatment. Black line: patients with low Foxp3+ cells (n = 15). Red line: patients with high Foxp3+ cells (n = 17). P = 0.537, log-rank test. (D) RFS rates after TURBT for high-risk NMIBC patients with intravesical BCG treatment. Black line: patients with low Foxp3+ cells (n = 10). Red line: patients with high Foxp3+ cells (n = 13). P = 0.070, log-rank test.